IGF-1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-12-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Receptor target | Growth hormone-releasing hormone receptor | G-protein-coupled receptor expressed on pituitary somatotroph cells |
| Primary signaling route | Cyclic AMP and protein kinase A | Increases intracellular calcium and promotes hormone release |
| Downstream marker | Insulin-like growth factor 1 | Blood concentration used as an integrated activity indicator |
| Study endpoint | Change in visceral adipose tissue | Assessed with computed tomography in trial populations |
| Research status | Investigational outside the approved indication | Trials in cognitive impairment did not meet primary endpoints |
Studies of the compound rely on imaging and laboratory endpoints rather than on symptoms alone. Visceral adipose tissue is usually quantified by computed tomography or magnetic resonance imaging at the level of the abdomen, with waist circumference serving as a cheaper but less specific proxy. Blood work tracks insulin-like growth factor 1, fasting glucose, glycated hemoglobin, and lipid fractions. In the pivotal trials the imaging endpoint fell by roughly fifteen to twenty percent over six months, subcutaneous fat changed little, and the visceral fat returned toward baseline after treatment stopped, a pattern that shapes how clinicians discuss durability.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
==== School of Global Journalism and Communication ==== Established in 2013, Morgan's School of Global Journalism and Communication is one of only two Maryland-based universities with an internationally accredited journalism school. The School of Global Journalism and Communication degree programs include journalism, strategic communications, and multiplatform production. The programs are accredited by the Accrediting Council on Education in Journalism and Mass Communications (ACEJMC), as recognized by the Association for Education in Journalism and Mass Communication (AEJMC). The school is also the host of the student-run newspaper The Spokesman, the university's radio station WMUR Baltimore, and its television network BEAR-TV.
=== Deformation === Timing deformation events is one of the important components in a tectonic study. Large scale cross-cutting relationships between rocks, dikes and plutons provide certain but relatively broad time constraints on deformation. Monazite can be incorporated into deformation fabrics, reaction textures and fractures; thus, studying microfabrics and microtextures of monazite offers a more straightforward method of dating a deformation event.
== Drug Interactions == Increased risk of adverse effects when used with alcohol. May potentiate the effects of general anaesthetics and anticoagulants, and prolong the action of neuromuscular blockers. May increase anticholinergic effects of atropine and drugs with anticholinergic activity. May increase risk of neurotoxicity when used with sibutramine or lithium. Avoid concurrent usage with drugs that cause QT prolongation or cardiac arrhythmias. May inhibit metabolism of TCAs. May antagonise effects of adrenaline and sympathomimetics, and reverse antihypertensive effects of guanethidine.
Sources: en.wikipedia.org
In 1979, the PLA fought Vietnam over a border skirmish in the Sino-Vietnamese War where both sides claimed victory. However, western analysts generally agree that Vietnam handily outperformed the PLA. During the Sino-Soviet split, strained relations between China and the Soviet Union resulted in bloody border clashes and mutual backing of each other's adversaries. China and Afghanistan had neutral relations with each other during the King's rule. When the pro-Soviet Afghan Communists seized power in Afghanistan in 1978, relations between China and the Afghan communists quickly turned hostile. The Afghan pro-Soviet communists supported China's enemies in Vietnam and blamed China for supporting Afghan anticommunist militants. China responded to the Soviet invasion of Afghanistan by supporting the Afghan mujahidin and ramping up their military presence near Afghanistan in Xinjiang. China acquired military equipment from the United States to defend itself from Soviet attacks. The PLA Ground Force trained and supported the Afghan Mujahideen during the Soviet-Afghan War, moving its training camps for the mujahideen from Pakistan into China itself. Hundreds of millions of dollars' worth of anti-aircraft missiles, rocket launchers, and machine guns were given to the Mujahideen by the Chinese. Chinese military advisors and army troops were also present with the Mujahideen during training.
== Chemistry == Several chemical factors affect the ionophore activity. The activity of an ionophore-metal complex depends on its geometric configuration and the coordinating sites and atoms which create coordination environment surrounding the metal center. This affects the selectivity and affinity towards a certain ion. Ionophores can be selective to a particular ion but may not be exclusive to it. Ionophores facilitate the transport of ions across biological membranes most commonly via passive transport, which is affected by lipophilicity of the ionophore molecule. The increase in lipophilicity of the ionophore-metal complex enhances its permeability through lipophilic membranes. The hydrophobicity and hydrophilicity of the complex also determines whether it will slow down or ease the transport of metal ions into cell compartments. The reduction potential of a metal complex influences its thermodynamic stability and affects its reactivity. The ability of an ionophore to transfer ions is also affected by the temperature.
== J == Nancy B. Jackson (1956–2022), American chemist who worked on heterogeneous catalysis and the development of alternative fuels Marilyn E. Jacox (1929–2013), American chemist who worked on the spectroscopy of free radicals and other unstable chemical species Hope Jahren (born 1969), American chemist and isotope analyst known for using stable isotope analysis to analyze fossil forests Paul Janssen (1926–2003), Belgian physician and entrepreneur who discovered the antispasmodic drug ambucetamide Allene Jeanes (1906–1995), American chemist who developed Dextran to replace plasma in the Korean War Frédéric Joliot-Curie (1900–1958), French chemist and physicist, 1935 Nobel Prize in Chemistry for the discovery of induced radioactivity Irène Joliot-Curie (1897–1956), French chemist and physicist, 1935 Nobel Prize in Chemistry for the discovery of induced radioactivity Madeleine M. Joullié (born 1927), French-American-Brazilian organic chemist who worked on synthesizing organic compounds such as tilorone, furanomycin, and numerous cyclopeptides Percy Lavon Julian (1899–1975), African American organic chemist who was a pioneer in the chemical synthesis of medicinal drugs from plants. He was the first to synthesize the natural product physostigmine.
Two pharmacological agents intended to prevent scarring in mild idiopathic fibrosis are pirfenidone, which reduced reductions in the 1-year rate of decline in FVC and reduced the decline in distances on the 6-minute walk test, but had no effect on respiratory symptoms, and is nintedanib, which acts as an antifibrotic, mediated through the inhibition of a variety of tyrosine kinase receptors (including platelet-derived growth factor, fibroblast growth factor, and vascular endothelial growth factor). A randomized clinical trial showed it reduced lung-function decline and acute exacerbations. Preclinical studies on monoclonal antibodies that target the pulmonary endothelial aggregation receptor 1 (PEAR1) (which plays a crucial role in fibroblast activation and the progression of fibrosis) have shown promising results in slowing disease progression and improving lung function. Anti-inflammatory agents have only limited success in reducing the fibrotic process. Some other types of fibrosis, such as non-specific interstitial pneumonia, may respond to immunosuppressive therapy such as corticosteroids. But only a minority of patients respond to corticosteroids alone, so additional immunosuppressants, such as cyclophosphamide, azathioprine, methotrexate, penicillamine, and cyclosporine may be used. Colchicine has also been used with limited success. Nerandomilast (Jascayd) was approved for medical use in the United States in October 2025.
Sources: en.wikipedia.org
It acts upstream at the pituitary receptor and depends on functioning somatotroph cells to produce any effect. Growth hormone injections bypass that step and deliver the hormone directly. The pharmacokinetic profiles and the resulting feedback on the body's own secretion therefore differ.
Insulin-like growth factor 1 is a downstream product of growth hormone action and changes more slowly than the hormone itself. Its blood concentration is used as an integrated indicator of whether the pathway has been stimulated. Interpretation requires attention to nutrition, illness, and other factors that shift IGF-1 independently.
No. The approved indication concerns excess visceral abdominal fat in adults with HIV infection and lipodystrophy, a specific clinical population. It is not cleared for general weight reduction or for cosmetic use. Studies in other groups remain investigational.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.